MCID: FNC007
MIFTS: 44

Functioning Pituitary Adenoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Functioning Pituitary Adenoma

MalaCards integrated aliases for Functioning Pituitary Adenoma:

Name: Functioning Pituitary Adenoma 12 58 15
Secretory Adenoma of the Pituitary Gland 12
Endocrine Active Pituitary Adenoma 58
Pituitary Adenoma, Functioning 71
Secreting Pituitary Adenoma 58

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:5395
NCIt 49 C8388
UMLS via Orphanet 72 C0854486
Orphanet 58 ORPHA314753
UMLS 71 C0854486

Summaries for Functioning Pituitary Adenoma

MalaCards based summary : Functioning Pituitary Adenoma, also known as secretory adenoma of the pituitary gland, is related to non-functioning pituitary adenoma and growth hormone secreting pituitary adenoma. An important gene associated with Functioning Pituitary Adenoma is SST (Somatostatin), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Octreotide and Pasireotide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and bone, and related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Functioning Pituitary Adenoma

Diseases related to Functioning Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 358)
# Related Disease Score Top Affiliating Genes
1 non-functioning pituitary adenoma 34.9 SST GHR GH1
2 growth hormone secreting pituitary adenoma 33.5 SSTR5 SSTR2 SST PRL POMC MEN1
3 tsh producing pituitary tumor 33.2 SSTR5 SSTR2 SSTR1 PRL GH1
4 functionless pituitary adenoma 32.5 SSTR5 SSTR2 SSTR1 SST POMC IGF1
5 pituitary adenoma 1, multiple types 32.2 SST PRL MEN1 IGF1 GH1 AIP
6 gigantism 31.3 PRL GH1 AIP
7 diabetes insipidus 30.9 PRL POMC GH1 CRH
8 familial isolated pituitary adenoma 30.9 MEN1 AIP
9 goiter 30.8 TRH SST PRL IGF1 GNAS
10 aip-related familial isolated pituitary adenomas 30.8 USP8 AIP
11 sexual disorder 30.7 PRL POMC DRD2
12 chromophobe adenoma 30.7 TRH PRL POMC GH1
13 empty sella syndrome 30.7 TRH PRL POMC IGF1 GH1
14 hypoadrenalism 30.7 POMC GH1 CRH
15 intracranial hypertension, idiopathic 30.6 SSTR1 POMC IGF1 GH1
16 lymphocytic hypophysitis 30.6 TBX19 POMC GH1
17 hypopituitarism 30.6 TRH TBX19 PRL POMC IGF1 GHR
18 pituitary tumors 30.5 SSTR5 SST PRL POMC MEN1 IGF1
19 hypothyroidism, congenital, nongoitrous, 4 30.5 PRL POMC GH1
20 fibrous dysplasia 30.5 SST PRL IGF1 GNAS GH1
21 gynecomastia 30.5 PRL POMC DRD2
22 pituitary apoplexy 30.4 SST PRL POMC MEN1 IGF1 GH1
23 adenoma 30.4 USP8 SSTR5 SSTR2 SST PRL POMC
24 galactorrhea 30.4 PRL IGF1 DRD2
25 islet cell tumor 30.4 SST MEN1 IGF1 GH1
26 isolated growth hormone deficiency 30.4 POMC IGF1 GHR GH1
27 gangliocytoma 30.4 PRL POMC CRH
28 acth-secreting pituitary adenoma 30.4 USP8 TBX19 SSTR5 SSTR2 SSTR1 SST
29 polycystic ovary syndrome 30.3 PRL POMC IGF1 GH1
30 uremia 30.3 MEN1 GHR GH1
31 acth-dependent cushing syndrome 30.3 USP8 PRL POMC CRH
32 craniopharyngioma 30.2 TRH PRL IGF1 GH1
33 hypoglycemia 30.2 SST PRL POMC IGF1 GH1 CRH
34 neuroendocrine tumor 30.2 SSTR2 SST POMC MEN1 IGF1
35 insulin-like growth factor i 30.2 SST PRL IGF1 GHR GH1
36 mccune-albright syndrome 30.2 SST PRL MEN1 IGF1 GNAS GHR
37 hydrocephalus 30.2 SST PRL IGF1 CRH
38 anxiety 30.1 PRL POMC DRD2 CRH
39 thyroid gland follicular carcinoma 30.0 SSTR5 SSTR2 SSTR1 SST MEN1
40 migraine with or without aura 1 30.0 PRL POMC DRD2 CRH
41 pituitary carcinoma 30.0 SSTR2 SST PRL POMC GNAS CRH
42 amenorrhea 30.0 TRH PRL POMC IGF1 CRH
43 thyroid carcinoma, familial medullary 29.9 SSTR5 SSTR2 SSTR1 SST MEN1
44 pituitary hormone deficiency, combined, 2 29.9 TRH TBX19 PRL POMC IGF1 GHR
45 hyperprolactinemia 29.9 TRH SST PRL POMC IGF1 GNAS
46 hypothyroidism 29.8 TRH SST PRL POMC IGF1 GNAS
47 hyperthyroidism 29.8 TRH SST PRL POMC IGF1 GNAS
48 multiple endocrine neoplasia, type i 29.8 SST PRL POMC MEN1 GNAS AIP
49 thyroid gland medullary carcinoma 29.7 SSTR5 SSTR2 SSTR1 SST POMC MEN1
50 nelson syndrome 29.5 USP8 SSTR5 SSTR2 SST PRL POMC

Graphical network of the top 20 diseases related to Functioning Pituitary Adenoma:



Diseases related to Functioning Pituitary Adenoma

Symptoms & Phenotypes for Functioning Pituitary Adenoma

MGI Mouse Phenotypes related to Functioning Pituitary Adenoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.27 AIP CRH DRD2 GHR GNAS IGF1
2 growth/size/body region MP:0005378 10.22 AIP CRH DRD2 GHR GNAS IGF1
3 endocrine/exocrine gland MP:0005379 10.21 AIP CRH DRD2 GHR GNAS IGF1
4 cardiovascular system MP:0005385 10.16 AIP DRD2 GHR GNAS IGF1 MEN1
5 integument MP:0010771 9.97 AIP CRH DRD2 GHR GNAS IGF1
6 liver/biliary system MP:0005370 9.91 AIP CRH DRD2 GHR GNAS MEN1
7 nervous system MP:0003631 9.77 CRH DRD2 GHR GNAS IGF1 MEN1
8 neoplasm MP:0002006 9.7 AIP DRD2 GNAS IGF1 MEN1 POMC
9 renal/urinary system MP:0005367 9.17 CRH DRD2 GHR GNAS IGF1 POMC

Drugs & Therapeutics for Functioning Pituitary Adenoma

Drugs for Functioning Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
2
Pasireotide Approved Phase 4 396091-73-9 9941444
3
Somatostatin Approved, Investigational Phase 4 51110-01-1, 38916-34-6 53481605
4
Metformin Approved Phase 4 657-24-9 14219 4091
5
Liraglutide Approved Phase 4 204656-20-2 44147092
6
Zinc Approved, Investigational Phase 4 7440-66-6 32051
7
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
8 Gastrointestinal Agents Phase 4
9 Antineoplastic Agents, Hormonal Phase 4
10 Hypoglycemic Agents Phase 4
11 insulin Phase 4
12 Insulin, Globin Zinc Phase 4
13 Incretins Phase 4
14 HIV Protease Inhibitors Phase 4
15
protease inhibitors Phase 4
16 Dipeptidyl-Peptidase IV Inhibitors Phase 4
17 Sitagliptin Phosphate Phase 4
18
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
19 Orange Approved Phase 3
20
lanreotide Approved Phase 3 108736-35-2
21 glucocorticoids Phase 2, Phase 3
22 Pharmaceutical Solutions Phase 3
23 Angiopeptin Phase 3
24
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
25
Bexarotene Approved, Investigational Phase 1, Phase 2 153559-49-0 82146
26
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
27
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
28
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
29 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
30
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
31
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
32
Sodium citrate Approved, Investigational Phase 2 68-04-2
33
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
34
Cabergoline Approved Phase 2 81409-90-7 54746
35
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
36
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
37
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
38
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
39
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
40
Enclomiphene Investigational Phase 2 15690-57-0
41
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
42 Antiemetics Phase 2
43 Autonomic Agents Phase 2
44 Trace Elements Phase 2
45 Micronutrients Phase 2
46 Vitamins Phase 2
47 Methylprednisolone Acetate Phase 2
48 Vitamin B3 Phase 2
49 Nutrients Phase 2
50 Neuroprotective Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 55)
# Name Status NCT ID Phase Drugs
1 Long-term (up to 3 Years) Clinical and Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues: Open-labeled, Prospective, Parallel Group Study Unknown status NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
2 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
3 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
4 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
5 A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
6 Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
7 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
8 A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
9 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape). Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
10 Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study Completed NCT01319994 Phase 2, Phase 3 Metformin;Placebo
11 An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome Recruiting NCT03621280 Phase 3 Levoketoconazole
12 Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699;LCI699 matching placebo
13 A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease Active, not recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
14 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
15 An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
16 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
17 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
18 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) Unknown status NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
19 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
20 An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma Completed NCT01283542 Phase 2 Pasireotide LAR
21 A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
22 Extension to a Multi-center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 μg Bid) and Doses of Open Label Sandostatin® (SMS) (100 μg Tid) in Acromegalic Patients Completed NCT00171730 Phase 2 Pasireotide
23 A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 Followed by a 12 - Week Treatment Period of LCI699 in Patients With Cushing's Disease Completed NCT01331239 Phase 2 LCI699
24 Clomiphene Citrate for Treatment of Acromegaly Not Controlled by Conventional Therapies Completed NCT02274311 Phase 2 Clomiphene Citrate
25 A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease Recruiting NCT03708900 Phase 2 LCI699
26 A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Recruiting NCT03774446 Phase 2 Seliciclib
27 A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2 Pasireotide with or without cabergoline
28 Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine Terminated NCT02160730 Phase 2 R-roscovitine
29 An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease Terminated NCT00612066 Phase 2 rosiglitazone maleate
30 Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma Withdrawn NCT01203618 Phase 2 Farletuzumab
31 A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma Terminated NCT02629549 Phase 1 OTL38
32 A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas Unknown status NCT03309319 Rosiglitazone
33 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332
34 Etat de santé Des Patients Suivis Pour Une Maladie de Cushing Dans la région Grand-Ouest de 1990 à 2015 Unknown status NCT03297892
35 Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease Unknown status NCT03346954
36 Cognitive Sequels of Cushing Syndrome Unknown status NCT02603653
37 Characterization of Receptors Present in Non-functioning Pituitary Macroadenomas by Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR) Unknown status NCT00852501
38 Investigation of Prevalence and Clinical Effects of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations With DNA Sequence Analysis in Acromegaly Patients in Turkey Unknown status NCT01902420
39 Characteristics of Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects Completed NCT02574793
40 Cognition, Steroids, and Imaging in Cushings Disease Completed NCT00081341
41 The Factors Associated With the Recurrence in Patients With Cushing Disease Completed NCT02233335
42 Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study Completed NCT01504399
43 National Swedish Study in Cushing´s Disease Incidence and Outcomes Completed NCT02350153
44 Seoul National University Pituitary Disease Cohort Study Recruiting NCT03474601
45 Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study) Recruiting NCT02310269 SOM230
46 Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms: Phase III Diagnostic Evaluation Study Recruiting NCT03974789
47 Modulating the Glucose-dependent Insulinotropic Polypeptide (GIP) System in Patients With Acromegaly Due to a Pituitary Tumor Recruiting NCT03807076
48 Evolution of the Metabolic, Cardiovascular, Bone Complications and of the Quality of Life in Cushing's Disease Recruiting NCT02568982
49 Treatment Outcomes for Patients With Cushing's Syndrome: a Prospective Data Collection Study Recruiting NCT03364803
50 Long-Term Follow UP of Survivors of Pediatric Cushing Disease Recruiting NCT03831958

Search NIH Clinical Center for Functioning Pituitary Adenoma

Genetic Tests for Functioning Pituitary Adenoma

Anatomical Context for Functioning Pituitary Adenoma

MalaCards organs/tissues related to Functioning Pituitary Adenoma:

40
Pituitary, Thyroid, Bone, Liver, Breast, Brain, Lung

Publications for Functioning Pituitary Adenoma

Articles related to Functioning Pituitary Adenoma:

(show top 50) (show all 211)
# Title Authors PMID Year
1
Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes involved in the regrowth of clinically non-functioning pituitary adenoma. 61
32015217 2020
2
Cut-off values for sufficient cortisol response to low dose Short Synacthen Test after surgery for non-functioning pituitary adenoma. 61
31907611 2020
3
Giant Non-Functioning Pituitary Adenoma: Clinical Characteristics and Therapeutic Outcomes. 61
31896156 2020
4
Giant Non-Functioning Pituitary Adenoma: Clinical Characteristics and Therapeutic Outcomes. 61
31931533 2020
5
Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles. 61
31796052 2019
6
Preoperative growth hormone (GH) peak values during a GH releasing peptide-2 test reflect the severity of hypopituitarism and the postoperative recovery of GH secretion in patients with non-functioning pituitary adenomas. 61
31776295 2019
7
An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy. 61
31741022 2019
8
T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma. 61
31655798 2019
9
Functioning Pituitary Adenoma with Xanthogranulomatous Features: Review of Literature and Case Report. 61
31534885 2019
10
Identification of CDK6 and RHOU in Serum Exosome as Biomarkers for the Invasiveness of Non-functioning Pituitary Adenoma. 61
31601299 2019
11
Cavernous sinus haemangioma with intrasellar extension mimicking non-functioning pituitary adenoma - A case report and review of literature. 61
31406488 2019
12
The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study. 61
31374549 2019
13
Significance of Elevated HMGB1 Expression in Pituitary Apoplexy. 61
31366550 2019
14
Unexpected concomitant pituitary adenoma and suprasellar meningioma: a case report and review of the literature. 61
31204511 2019
15
Autoimmune thyroid diseases are more common in patients with prolactinomas: a retrospective case-control study in an Italian cohort. 61
30406929 2019
16
Endocrinological Outcome of Endoscopic Transsphenoidal Surgery for Functioning and Non-Functioning Pituitary Adenoma. 61
31303851 2019
17
Predicting the regrowth of clinically non-functioning pituitary adenoma with a statistical model. 61
31109334 2019
18
Pre-operative MRI predictors of hormonal remission status post pituitary adenoma resection. 61
30731423 2019
19
The burden of disease for pituitary patients. 61
31405752 2019
20
Quality of Life but not Cognition is Impacted by Radiotherapy in Patients with Non-Functioning Pituitary Adenoma. 61
30861564 2019
21
Incidence rate and risk factors of early repolarization in patients with growth hormone-secreting pituitary adenoma: a cohort study. 61
30643415 2019
22
Genome-wide identification of lncRNAs and mRNAs differentially expressed in non-functioning pituitary adenoma and construction of an lncRNA-mRNA co-expression network. 61
30504132 2019
23
Intractable Rathke's cleft cyst hidden behind co-existing giant pituitary adenoma - Case report. 61
30610983 2019
24
A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma. 61
30542712 2019
25
Endocrinological Outcomes of Intraoperative MRI-Guided Endoscopic Transsphenoidal Surgery for Non-Functioning Pituitary Adenoma. 61
30649793 2019
26
FGFR2 gene polymorphism rs2981582 is associated with non-functioning pituitary adenomas in Chinese Han population: a case-control study. 61
30206133 2018
27
Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis. 61
30590584 2018
28
Spindle cell oncocytoma of the neurohypophysis with metastasis to the sphenoparietal sinus and immunohistochemical negativity for S100 and epithelial membrane antigen (EMA). 61
30431381 2018
29
Comorbidities in patients with non-functioning pituitary adenoma: influence of long-term growth hormone replacement 61
30299891 2018
30
Non-invasive radiomics approach potentially predicts non-functioning pituitary adenomas subtypes before surgery. 61
29572634 2018
31
Postoperative growth hormone dynamics in clinically nonfunctioning pituitary adenoma. 61
29910227 2018
32
Comorbidities in patients with non-functioning pituitary adenoma: influence of long-term growth hormone replacement. 61
30049813 2018
33
Data of phosphoproteomic analysis of non-functioning pituitary adenoma. 61
29900237 2018
34
Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant? 61
29318507 2018
35
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS. 61
29498920 2018
36
How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review. 61
29302835 2018
37
Mortality in patients with non-functioning pituitary adenoma. 61
29344906 2018
38
Effects of active acromegaly on bone mRNA and microRNA expression patterns. 61
29374071 2018
39
Spectrum of Pituitary disorders: A retrospective study from Basrah, Iraq. 61
30026929 2018
40
Interpretation of Serum Gonadotropin Levels in Hyperprolactinaemia. 61
29660734 2018
41
Pituitary Carcinoma in a Patient with an SDHB Mutation. 61
28284009 2017
42
Amelanotic melanocytoma of the sella mimicking pituitary adenoma. 61
28853696 2017
43
In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism. 61
28634279 2017
44
Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma. 61
28596421 2017
45
Prevalence, Clinical Features, and Natural History of Incidental Clinically Non-Functioning Pituitary Adenomas. 61
28759937 2017
46
Pituitary adenoma with adipose tissue: A new metaplastic variant. 61
28070930 2017
47
The impact on cognitive functions of patients with pituitary adenoma before and after surgery. 61
28478494 2017
48
Non-functioning pituitary adenoma underwent surgery: A multicenter retrospective study over the last four decades (1977-2015). 61
28389053 2017
49
Incidence of malignant tumours in patients with a non-functioning pituitary adenoma. 61
28274953 2017
50
Time trends of mortality in patients with non-functioning pituitary adenoma: a Swedish nationwide study. 61
27743172 2017

Variations for Functioning Pituitary Adenoma

Expression for Functioning Pituitary Adenoma

Search GEO for disease gene expression data for Functioning Pituitary Adenoma.

Pathways for Functioning Pituitary Adenoma

Pathways related to Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 USP8 TRH SSTR5 SSTR2 SSTR1 SST
2
Show member pathways
13.22 TRH SSTR5 SSTR2 SSTR1 SST PRL
3
Show member pathways
12.61 USP8 POMC MEN1 GNAS CRH AIP
4
Show member pathways
11.87 SSTR5 SSTR2 SSTR1 SST POMC IGF1
5 11.83 SSTR5 SSTR2 SSTR1 SST POMC GNAS
6 11.59 TBX19 POMC GNAS CRH
7 11.47 IGF1 GHR GH1
8 11.41 IGF1 GNAS CRH
9
Show member pathways
11.19 PRL GHR GH1
10 10.73 PRL POMC DRD2
11 10.28 POMC CRH

GO Terms for Functioning Pituitary Adenoma

Cellular components related to Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 TRH SST PRL POMC IGF1 GNAS
2 extracellular space GO:0005615 9.61 SST PRL POMC MIR199A1 MIR142 IGF1
3 growth hormone receptor complex GO:0070195 8.62 GHR GH1

Biological processes related to Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.81 TRH SSTR5 SSTR2 SSTR1 SST POMC
2 negative regulation of cell proliferation GO:0008285 9.8 SSTR5 SSTR2 SSTR1 SST MEN1 DRD2
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.75 IGF1 GHR GH1
4 female pregnancy GO:0007565 9.74 PRL GNAS CRH
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.7 IGF1 GHR GH1
6 signal transduction GO:0007165 9.7 TRH SSTR5 SSTR2 SSTR1 PRL POMC
7 forebrain development GO:0030900 9.69 SSTR2 SSTR1 DRD2
8 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.67 SSTR5 SSTR2 SSTR1
9 neuropeptide signaling pathway GO:0007218 9.67 SSTR5 SSTR2 SSTR1 POMC
10 positive regulation of multicellular organism growth GO:0040018 9.63 GHR GH1 DRD2
11 positive regulation of JAK-STAT cascade GO:0046427 9.61 PRL GHR GH1
12 positive regulation of cAMP-mediated signaling GO:0043950 9.6 GNAS CRH
13 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.59 MIR199A1 IGF1
14 insulin-like growth factor receptor signaling pathway GO:0048009 9.58 IGF1 GHR
15 regulation of multicellular organism growth GO:0040014 9.58 PRL IGF1 GHR
16 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.56 IGF1 GH1
17 growth hormone receptor signaling pathway GO:0060396 9.55 GHR GH1
18 peristalsis GO:0030432 9.54 SSTR2 DRD2
19 hormone-mediated apoptotic signaling pathway GO:0008628 9.48 SST CRH
20 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.43 PRL GHR GH1
21 somatostatin signaling pathway GO:0038170 8.8 SSTR5 SSTR2 SSTR1

Molecular functions related to Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide binding GO:0042277 9.54 SSTR5 SSTR2 SSTR1
2 insulin-like growth factor receptor binding GO:0005159 9.4 IGF1 GNAS
3 neuropeptide binding GO:0042923 9.33 SSTR5 SSTR2 SSTR1
4 corticotropin-releasing hormone receptor 1 binding GO:0051430 9.32 GNAS CRH
5 prolactin receptor binding GO:0005148 9.26 PRL GH1
6 hormone activity GO:0005179 9.17 TRH SST PRL POMC IGF1 GH1
7 somatostatin receptor activity GO:0004994 9.13 SSTR5 SSTR2 SSTR1

Sources for Functioning Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....